Aurobindo Pharma arm terminates agreement with Hilleman Labs Singapore for pentavalent vaccine
Hyderabad: Aurobindo Pharma has announced that Auro Vaccines Private Limited, a wholly owned step-down subsidiary of the Company, has terminated the License Agreement entered in September with Hilleman Laboratories Singapore Pte, Limited to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.
Pentavalent vaccine provides protection to a child from 5 life-threatening diseases – Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib.
Read also: Aurobindo Pharma arm, Hilleman Labs Singapore ink pact for paediatric pentavalent vaccine
"Please note that Auro Vaccines Private Limited is not a material subsidiary to the Company and the termination of a Licence Agreement for a very early-stage vaccine asset is not a material event. It may also be noted that this termination of Agreement will not have any significant impact on the Company and/or its subsidiaries or its financials. In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures," Aurobindo noted in a BSE filing.
Medical Dialogues team had earlier reported that the European Commission (EC) has granted marketing authorization in the European Union (EU) for Zefylti, a filgrastim biosimilar, to CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma.
Earlier in December 2024, the Committee for Medicinal Products (CHMP) of EuropeanMedicines Agency has adopted positive opinion recommending the approval of Zefylti.
Read also: Aurobindo Pharma to Begin European Supply from China Facility in April
Auro Vaccines LLC is a clinical-stage vaccine development company. The Company's goal is the development and commercialization of safe and highly effective vaccines to treat and prevent viral diseases, and transformational oncolytic vaccines that unleash the body’s own immune system to attack cancer. It focuses on major and emerging infectious diseases of public health and biodefense importance and advanced-stage cancers that are not adequately addressed using current approaches.
Read also: Aurobindo Pharma to acquire 26 percent stake in solar energy company
